MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • PROLOR Biotech, Inc. (PBTH) Reports Positive Results For Diabetes Drug Candidate 0 comments
    Apr 17, 2012 2:28 PM | about stocks: PBTH

    PROLOR Biotech is a clinical stage biopharmaceutical company using unique technologies, including its patented CTP technology, to develop longer-acting proprietary versions of already approved therapeutic proteins. The company's CTP technology is applicable to virtually all proteins.

    The company today reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate, MOD-6030. The study was set up to track the potential therapeutic effect of the drug when injected once weekly as measured by weight loss, reduction in food intake, glycemic control, and cholesterol levels. MOD-6030 is a long-acting version of oxyntomodulin, a naturally occurring hormone that acts as a natural signal to reduce food intake and increase energy expenditure following the ingestion of food.

    In the study, MOD-6030 was administered to diet-induced obese mice once a week over a 30-day period. The results were that the drug showed significant efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity, and reducing cholesterol levels as compared to a control group that received a placebo. The mice receiving MOD-6030 achieved on average a 28% weight loss, a 29% reduction in food intake, a 19% drop in blood glucose levels, a 57% reduction in cholesterol levels, and a significant loss in body fat.

    The study is great news for PROLOR Biotech. The company's CEO Dr. Abraham Havron said, "We believe there is great demand among obese patients and their physicians for therapies that will help patients lose weight and reduce elevated glucose levels."

    For further information about PROLOR Biotech and all its potential drug candidates, please visit the company's website at www.prolor-biotech.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: PBTH
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.